Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination

Dechi Jean-Jacques Renaud; Toni Thomas D'Aquin; Cisse-Camara Massara; N'din Jean-Louis Philippe; Ake Aya Jeanne Armande; Siransy Kouabla Liliane; Sekongo Yassongui Mamadou; Gogbe Leto Olivier; Brou Emmanuel; Fieni Flore; Wawa Amedee Junior; Aby Roland; Kouakou Kouadio; Chenal Henri

doi:doi:10.11648/j.bmb.20220704.11

Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination

Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, Siransy Kouabla Liliane, Sekongo Yassongui Mamadou, Gogbe Leto Olivier, Brou Emmanuel, Fieni Flore, Wawa Amedee Junior, Aby Roland, Kouakou Kouadio, Chenal Henri

Published in Biochemistry and Molecular Biology (Volume 7, Issue 4)

Received: 15 September 2022 Accepted: 4 October 2022 Published: 17 October 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.

Published in	Biochemistry and Molecular Biology (Volume 7, Issue 4)
DOI	10.11648/j.bmb.20220704.11
Page(s)	70-74
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

HIV-1, NRTI Resistance Mutation, Switched to Dolutegravir (DTG) Therapy

References

[1]	Myburgh, H., Reynolds, L., Hoddinott, G., van Aswegen, D., Grobbelaar, N., Gunst, C., Jennings, K., Kruger, J., Louis, F., Mubekapi-Musadaidzwa, C., Viljoen, L., Wademan, D., & Bock, P. (2021). Implementing 'universal' access to antiretroviral treatment in South Africa: a scoping review on research priorities. Health Policy Plan, 36 (6), 923-938. doi: 10.1093/heapol/czaa094.
[2]	De Clercq, J., Rutsaert, S., De Scheerder, M.-A., Verhofstede, C., Callens, S., & Vandekerckhove, L. (2020). Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clinica Belgica, 77 (1), 168-176. doi: 10.1080/17843286.2020.1770413.
[3]	Ministry of Health and Public Hygiene (MSHP). The “Test and Treat All” approach in the context of the Care and Support of PLHIV in Côte d’Ivoire. Circular Note N°0001/MSHP/DGS/PNLS/DC of 07 February 2017 for the attention of Health Providers.
[4]	World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1; 2019
[5]	Mbhele, N., Chimukangara, B., & Gordon, M. (2021). HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents, 57 (5), 106343. doi: 10.1016/j.ijantimicag.2021.106343.
[6]	Laskey, S. B. & Siliciano, R. F. (2016). Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight, 1 (19): e90033. doi: 10.1172/jci.insight.90033.
[7]	Pham, H., T., Mesplède, T., & Wainberg, M., A. (2016). Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology, 13 (1), 31. doi: 10.1186/s12977-016-0265-x.
[8]	Malet, I., Thierry, E., Wirden, M., Lebourgeois, S., Subra, F., Katlama, C., Deprez, E., Calvez, V., Marcelin, A., G., & Delelis, O. (2015). Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother, 70 (10), 2870-80. doi: 10.1093/jac/dkv197.
[9]	Ndashimye, E., & Arts, E. J. (2021). Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings. International Journal of Infectious Diseases, 105, 298–303. doi: 10.1016/j.ijid.2021.03.018.
[10]	Blanco, J. L., Rojas, J., Paredes, R., Negredo, E., Mallolas, J., Casadella, M., Clotet, B., Gatell, J. M., de Lazzari, E., Martinez, E., & DOLAM Study Team (2018). Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. The Journal of antimicrobial chemotherapy, 73 (7), 1965–1971. https://doi.org/10.1093/jac/dky093.
[11]	Hocqueloux, L., Raffi, F., Prazuck, T., Bernard, L., Sunder, S., Esnault, J. L., Rey, D., Le Moal, G., Roncato-Saberan, M., André, M., Billaud, E., Valéry, A., Avettand-Fènoël, V., Parienti, J. J., Allavena, C., & MONCAY study group (2019). Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 69 (9), 1498–1505. https://doi.org/10.1093/cid/ciy1132
[12]	Nagami, E. H., Thakarar, K., & Sax PE. (2021). Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance. Open Forum Infectious Diseases, 9 (2), ofab648. doi: 10.1093/ofid/ofab648.
[13]	Wijting, I., Rokx, C., Boucher, C., van Kampen, J., Pas, S., de Vries-Sluijs, T., Schurink, C., Bax, H., Derksen, M., Andrinopoulou, E. R., van der Ende, M., van Gorp, E., Nouwen, J., Verbon, A., Bierman, W., & Rijnders, B. (2017). Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. The lancet. HIV, 4 (12), e547–e554. https://doi.org/10.1016/S2352-3018(17)30152-2

Cite This Article

Plain Text BibTeX RIS

APA Style

Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. (2022). Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology, 7(4), 70-74. https://doi.org/10.11648/j.bmb.20220704.11

Copy | Download

ACS Style

Dechi Jean-Jacques Renaud; Toni Thomas D'Aquin; Cisse-Camara Massara; N'din Jean-Louis Philippe; Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem. Mol. Biol. 2022, 7(4), 70-74. doi: 10.11648/j.bmb.20220704.11

Copy | Download

AMA Style

Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem Mol Biol. 2022;7(4):70-74. doi: 10.11648/j.bmb.20220704.11

Copy | Download

@article{10.11648/j.bmb.20220704.11,
  author = {Dechi Jean-Jacques Renaud and Toni Thomas D'Aquin and Cisse-Camara Massara and N'din Jean-Louis Philippe and Ake Aya Jeanne Armande and Siransy Kouabla Liliane and Sekongo Yassongui Mamadou and Gogbe Leto Olivier and Brou Emmanuel and Fieni Flore and Wawa Amedee Junior and Aby Roland and Kouakou Kouadio and Chenal Henri},
  title = {Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination},
  journal = {Biochemistry and Molecular Biology},
  volume = {7},
  number = {4},
  pages = {70-74},
  doi = {10.11648/j.bmb.20220704.11},
  url = {https://doi.org/10.11648/j.bmb.20220704.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20220704.11},
  abstract = {Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination
AU  - Dechi Jean-Jacques Renaud
AU  - Toni Thomas D'Aquin
AU  - Cisse-Camara Massara
AU  - N'din Jean-Louis Philippe
AU  - Ake Aya Jeanne Armande
AU  - Siransy Kouabla Liliane
AU  - Sekongo Yassongui Mamadou
AU  - Gogbe Leto Olivier
AU  - Brou Emmanuel
AU  - Fieni Flore
AU  - Wawa Amedee Junior
AU  - Aby Roland
AU  - Kouakou Kouadio
AU  - Chenal Henri
Y1  - 2022/10/17
PY  - 2022
N1  - https://doi.org/10.11648/j.bmb.20220704.11
DO  - 10.11648/j.bmb.20220704.11
T2  - Biochemistry and Molecular Biology
JF  - Biochemistry and Molecular Biology
JO  - Biochemistry and Molecular Biology
SP  - 70
EP  - 74
PB  - Science Publishing Group
SN  - 2575-5048
UR  - https://doi.org/10.11648/j.bmb.20220704.11
AB  - Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.
VL  - 7
IS  - 4
ER  -

Copy | Download

Author Information

Dechi Jean-Jacques Renaud

National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast
Toni Thomas D'Aquin

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Cisse-Camara Massara

Unit of Training and Research in Medical Sciences, Felix Houphouet Boigny University, Abidjan, Ivory Coast
N'din Jean-Louis Philippe

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Ake Aya Jeanne Armande

National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast
Siransy Kouabla Liliane

National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast
Sekongo Yassongui Mamadou

National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast
Gogbe Leto Olivier

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Brou Emmanuel

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Fieni Flore

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Wawa Amedee Junior

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Aby Roland

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Kouakou Kouadio

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast
Chenal Henri

Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. (2022). Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology, 7(4), 70-74. https://doi.org/10.11648/j.bmb.20220704.11

Copy | Download

ACS Style

Dechi Jean-Jacques Renaud; Toni Thomas D'Aquin; Cisse-Camara Massara; N'din Jean-Louis Philippe; Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem. Mol. Biol. 2022, 7(4), 70-74. doi: 10.11648/j.bmb.20220704.11

Copy | Download

AMA Style

Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem Mol Biol. 2022;7(4):70-74. doi: 10.11648/j.bmb.20220704.11

Copy | Download

@article{10.11648/j.bmb.20220704.11,
  author = {Dechi Jean-Jacques Renaud and Toni Thomas D'Aquin and Cisse-Camara Massara and N'din Jean-Louis Philippe and Ake Aya Jeanne Armande and Siransy Kouabla Liliane and Sekongo Yassongui Mamadou and Gogbe Leto Olivier and Brou Emmanuel and Fieni Flore and Wawa Amedee Junior and Aby Roland and Kouakou Kouadio and Chenal Henri},
  title = {Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination},
  journal = {Biochemistry and Molecular Biology},
  volume = {7},
  number = {4},
  pages = {70-74},
  doi = {10.11648/j.bmb.20220704.11},
  url = {https://doi.org/10.11648/j.bmb.20220704.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20220704.11},
  abstract = {Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination
AU  - Dechi Jean-Jacques Renaud
AU  - Toni Thomas D'Aquin
AU  - Cisse-Camara Massara
AU  - N'din Jean-Louis Philippe
AU  - Ake Aya Jeanne Armande
AU  - Siransy Kouabla Liliane
AU  - Sekongo Yassongui Mamadou
AU  - Gogbe Leto Olivier
AU  - Brou Emmanuel
AU  - Fieni Flore
AU  - Wawa Amedee Junior
AU  - Aby Roland
AU  - Kouakou Kouadio
AU  - Chenal Henri
Y1  - 2022/10/17
PY  - 2022
N1  - https://doi.org/10.11648/j.bmb.20220704.11
DO  - 10.11648/j.bmb.20220704.11
T2  - Biochemistry and Molecular Biology
JF  - Biochemistry and Molecular Biology
JO  - Biochemistry and Molecular Biology
SP  - 70
EP  - 74
PB  - Science Publishing Group
SN  - 2575-5048
UR  - https://doi.org/10.11648/j.bmb.20220704.11
AB  - Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.
VL  - 7
IS  - 4
ER  -

Copy | Download